Department of Medicine, UCLA Lung Cancer Research Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Molecular Gene Medicine Laboratory, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Adv Exp Med Biol. 2020;1231:67-78. doi: 10.1007/978-3-030-36667-4_7.
CCL21 promotes immune activity in the tumor microenvironment (TME) by colocalizing dendritic cells (DC) and T cells programing ectopic lymph node architectural structures that correlate with cancer prognosis. Innovative strategies to deliver CCL21 in cancer patients will reactivate the downregulated immune activity in the TME. Immune escape mechanisms are upregulated in the TME that promote tumor immune evasion. CCL21 combined with inhibition of dominant pathways of immune evasion will aid in the development of effective immunotherapy for cancer.
CCL21 通过募集树突状细胞（DC）和 T 细胞，在肿瘤微环境（TME）中促进免疫活性，从而程序化异位淋巴结结构，与癌症预后相关。在癌症患者中递送 CCL21 的创新策略将重新激活 TME 中下调的免疫活性。在 TME 中上调的免疫逃逸机制促进了肿瘤的免疫逃逸。CCL21 与抑制免疫逃逸的主导途径相结合，将有助于开发有效的癌症免疫疗法。
